Immune Response News and Research

RSS

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

The efficacy and safety of a DNA-based vaccine are investigated, finding that the unique vaccine imparts a robust and long-lasting immunogenic response.

15 Oct 2021

Phase 2 study shows safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine

The results of a phase 2 clinical trial featuring a SARS-CoV-2 recombinant protein vaccine developed by GlaxoSmithKline are reported, demonstrating a favorable immune response amongst both naïve and non-naïve adults with an acceptable safety profile.

15 Oct 2021

Cell-based quadrivalent influenza vaccine produces sufficient immune response in children

A cell-based influenza vaccine has effectively provided protection against the flu in children and adolescents, according to a new study.

15 Oct 2021

Study reveals a detrimental role of the immune system in Lewy body dementias

T-cells respond to buildups of alpha-synuclein, the aggregated protein clumps that are a feature of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease (PD), according to a Northwestern Medicine study published in Science.

14 Oct 2021

SARS-CoV-2 induces tissue immune memory

A new study reports that the SARS-CoV-2 induces protective tissue memory that includes both humoral and cellular elements to protect specific tissue sites.

14 Oct 2021

Increased transmission in open spike conformations of SARS-CoV-2 variants

Researchers from Yale University and the University of Texas have collaborated to investigate mutations in some VOCs.

14 Oct 2021

Mutation of cysteine residues in NRP1 reduces SARS-CoV-2 spike protein entry into cells

Researchers have been investigating altered protein conformations in variants of concern to provide further insight for future therapies against COVID-19.

14 Oct 2021

COVID-19 booster for immunosuppressed patients with inflammatory bowel disease

Researchers have published correspondence detailing the reasoning behind providing a third booster dose to patients with inflammatory bowel disease that have been treated with drugs that can reduce the response to the COVID-19 vaccines.

14 Oct 2021

New study finds SARS-CoV-2 causes retinal infection

Can coronavirus disease 2019 (COVID-19) affect the eye? New research suggests the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can enter the eye and infect photoreceptor and retinal ganglion cells. In addition, SARS-CoV-2 infection increases the expression of several inflammatory genes, including the cytokine interleukin 33 (IL33), which is linked to COVID-19 disease and retinal degeneration.

13 Oct 2021

How long does natural immunity produced by SARS-CoV-2 infection last?

A new study posted to the bioRxiv* preprint server followed the adaptive immune response in convalescent patients from Swedish and Italian cohorts—which had earlier shown long-lasting adaptive immune responses to the G614 strain—for 15 months. Here, specific antibody levels and neutralizing antibody titers were tested against variants of concern (VOCs).

12 Oct 2021

Rapid measurement of SARS-CoV-2 spike T-cells

Researchers measure SARS-CoV-2 T-cell responses in individuals vaccinated or in those who developed immunity from a prior natural infection.

12 Oct 2021

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Researchers review diverse computational methods for drug/inhibitor design and enzymes as potential targets for inhibitors to treat coronaviruses diseases.

12 Oct 2021

Vaccinated children induced significantly higher antibody titers than naturally SARS-CoV-2 infected children

A recent preprint discusses the antibody response to the nucleic acid vaccines against SARS-CoV-2 when administered to children aged 7-11 years.

12 Oct 2021

Nucleoside modifications suppress the potential of RNA to activate dendritic cells

A new paper shows that human TLR3, TLR7, and TLR8 receptors are activated with naturally occurring RNA, but this is eliminated once modified nucleosides such as m5C, m6A, m5U s2U, or pseudouridine are incorporated.

12 Oct 2021

A new bacterial two-hybrid assay to study SARS-CoV-2 interactome

Recently, scientists have developed a bacterial two-hybrid (B2H) system to study the PPIs of SARS-CoV-2 in a heterologous non-eukaryotic system. This study is available on the bioRxiv* preprint server. Put simply, the B2H system could be used to analyze the SARS-CoV-2 proteome.

11 Oct 2021

Research provides insights on colorectal cancers’ immunotherapy resistance

Immune checkpoint inhibitors, which unleash the immune response against tumor cells, have revolutionized cancer treatment; however, the medications aren't effective in a large number of patients, including those with colorectal cancer.

11 Oct 2021

An investigation of SARS-CoV-2 infection in diabetic pregnancies

Researchers discuss the basic and clinical science of the potential inter-relationships between diabetes mellitus and COVID-19 in pregnancies.

11 Oct 2021

Formal health care transition programs needed to provide uninterrupted support for youth with Kawasaki disease

Kawasaki disease is the most common cause of acquired heart disease that develops in early childhood, creating inflammation in blood vessels, particularly heart arteries.

11 Oct 2021

New molecular understanding of variations in salmonella virulence

Researchers from the University of Seville, in collaboration with the universities of Zaragoza and Kansas (USA), have managed to describe hitherto unknown processes that allow us to understand the virulence of a Salmonella infection.

11 Oct 2021

Research finds different antibody responses following COVID vaccination and natural infection

A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth.

10 Oct 2021

Immune Response News and Research

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

Phase 2 study shows safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine

Cell-based quadrivalent influenza vaccine produces sufficient immune response in children

Study reveals a detrimental role of the immune system in Lewy body dementias

SARS-CoV-2 induces tissue immune memory

Increased transmission in open spike conformations of SARS-CoV-2 variants

Mutation of cysteine residues in NRP1 reduces SARS-CoV-2 spike protein entry into cells

COVID-19 booster for immunosuppressed patients with inflammatory bowel disease

New study finds SARS-CoV-2 causes retinal infection

How long does natural immunity produced by SARS-CoV-2 infection last?

Rapid measurement of SARS-CoV-2 spike T-cells

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Vaccinated children induced significantly higher antibody titers than naturally SARS-CoV-2 infected children

Nucleoside modifications suppress the potential of RNA to activate dendritic cells

A new bacterial two-hybrid assay to study SARS-CoV-2 interactome

Research provides insights on colorectal cancers’ immunotherapy resistance

An investigation of SARS-CoV-2 infection in diabetic pregnancies

Formal health care transition programs needed to provide uninterrupted support for youth with Kawasaki disease

New molecular understanding of variations in salmonella virulence

Research finds different antibody responses following COVID vaccination and natural infection

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News